TABLE 4.
Predicted performance of genotypic approach across U.S. geographic regionsa
| Census region | Ceftriaxone |
Meropenem |
TZP |
|||
|---|---|---|---|---|---|---|
| NS (n) | % VME | NS (n) | % VME | NS (n) | % VME | |
| New England | 42 | 42.86 | 4 | 25.00 | 23 | 60.87 |
| Mid-Atlantic | 255 | 12.16 | 116 | 3.45 | 166 | 9.64 |
| East North Central | 80 | 25.00 | 13 | 7.69 | 31 | 41.94 |
| West North Central | 27 | 33.33 | 0 | NA | 8 | 75.00 |
| South Atlantic | 38 | 28.95 | 5 | 0.00 | 21 | 47.62 |
| East South Central | 51 | 27.45 | 1 | 0.00 | 12 | 66.67 |
| West South Central | 131 | 18.32 | 23 | 30.43 | 56 | 23.21 |
| Mountain | 23 | 26.09 | 2 | 0.00 | 7 | 57.14 |
| Pacific | 55 | 21.82 | 1 | 0.00 | 19 | 47.37 |
| Overall | 702 | 20.66 | 165 | 7.27 | 343 | 27.11 |
a
The genotypic approach includes detection of CTX-M, KPC, and/or NDM for ceftriaxone and TZP, KPC, or NDM for meropenem. NS, nonsusceptible; NA, not applicable.